Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer

Giuseppe Di Lorenzo, Carmine Pizza, Riccardo Autorino, Michele De Laurentiis, Ombretta Marano, Adele D'Alessio, Giuseppe Cancello, Vincenzo Altieri, Giampaolo Tortora, Sisto Perdonà, Angelo Raffaele Bianco, Sabino De Placido

Research output: Contribution to journalArticlepeer-review


The current study investigated the clinical benefit, the impact on biochemical and objective response and tolerability of weekly docetaxel with vinorelbine (VIN-DOX) in symptomatic patients with hormone refractory prostate cancer (HRPC). Patients were treated with docetaxel 25 mg/m 2 and vinorelbine 20 mg/m 2, intravenously for 6 consecutive weeks followed by a 2 week rest repeatedly until disease progression. Clinical benefit evaluations, based on Karnofsky performance status (KPS) and pain measure, were assessed weekly during therapy. A clinical benefit response was defined as a sustained (≥4 weeks) improvements in one of these parameters. Changes in prostate-specific antigen (PSA) levels, tumoral response and toxicity also were evaluated. 19 men (median age 68 years), were treated. Overall, 42% of patients achieved a KPS significant change and positive pain response; 47% achieved a 50% or greater reduction in PSA. The objective response rate was observed in 2 of 9 patients with measurable disease (22%). The most important toxicity was neutropenia (Grade 3 = 32%). The combination of weekly VIN-DOX appears to be feasible. VIN-DOX was found to be associated with improvement in clinical benefit response and biochemical response and well tolerated as first line treatment in HRPC.

Original languageEnglish
Pages (from-to)712-716
Number of pages5
JournalEuropean Urology
Issue number6
Publication statusPublished - Dec 2004


  • Chemotherapy
  • Clinical benefit
  • Hormone refractory prostate cancer

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer'. Together they form a unique fingerprint.

Cite this